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Abstract: The Fc Receptor-like Y (FcRY) molecule is preferentially expressed by B lymphocytes and has re-
cently been considered as a potential therapeutic target for B cell malignancies. In this study, we investigated the
correlation between FcRY expression profile, B lymphocytes population and different HBV infection disease
status. The FcRY expression level on B lymphocytes and the number of B lymphocytes population from periph-
eral blood in 27 healthy controls (HC) and 65 patients with HBV-induced diseases, including chronic hepatitis B
(CHB), liver cirrhosis (LC) and hepatocellular carcinoma (HCC), were analyzed using quantitative real-time
PCR and flow cytometry. The results showed the level of FcRY expression and frequency of germinal center
(GC) B lymphocytes from peripheral blood were significantly correlated with the HBV-related disease status,
which was highest in HCC and LC patients, lowest in healthy donors, and in the middle in patients with CHB.
Our study indicates that there is a significant correlation between FcRY expression profile, B lymphocytes pop-
ulation and HBV-induced diseases. However, the roles of FcRY and B lymphocytes in HBV-induced diseases
are unclear and need further investigation. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 3, pp. 405–409)
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Introduction
Hepatitis B virus (HBV) infection is highly prevalent
worldwide, especially in the Asia-Pacific region, and
is a major cause of morbidity and death. It is estimat-
ed that two billion people globally have been infect-
ed with HBV and tens of millions of new cases occur
annually. Of those infected, 15% to 40% could de-
velop into liver cirrhosis (LC) or hepatocellular car-
cinoma (HCC) [1–3]. Due to its significant economic
and public health impact, the control and prevention
of hepatitis B continues to be a major concern.
The cellular and molecular mechanisms of HBV
infection have been investigated and it is now widely
accepted that the adaptive immune responses, par-
ticularly the cellular immune response, play key roles
in the development of immunity to HBV.
CD4 T cells, classically referred to as helper T cells,
are robust producers of cytokines, while CD8 T cells
go on to clear HBV-infected hepatocytes through cy-
tolytic and non-cytolytic mechanisms, reducing the
levels of circulating virus [4, 5]. Despite the cellular
immune response being a major contributor to HBV
clearance, humoral responses by B lymphocytes are
also important in controlling HBV [6]. In addition to
the production of antibodies, little is known about the
role of B lymphocytes such as differentiation, matu-
ration and function during the natural course of HBV
infection.
Fc receptor-like (FCRL) molecules are a family
of Fc receptor homologs comprising eight structural-
ly related members [7–10]. Seven of the eight FCRL
family members are preferentially expressed by B cells
at different stages in their development, the excep-
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tion being FCRL6 [11–17]. FcRY, also known as
FREB2 and FCRLB, is one of the FCRL family mem-
bers and found to be an intracellular protein consist-
ing of three immunoglobulin-like domains and a car-
boxy terminal mucin-like domain. The analysis of
FcRY expression within human tonsils indicates that
this protein is mainly expressed in subset of germinal
center (GC) B cells, which suggests that it may play
an important role in regulating cellular differentia-
tion and modulating the initiation and termination
of B-cell responses [18–20].
Recent studies indicate that the activated level of
B cells in human peripheral blood lymphocytes with
HBV infection is higher than that of normal controls
[21]. Based on that finding, we hypothesize that HBV
infection might alter the proportion of B cells sub-
population and thus influence the expression level of
FcRY. In this report, we investigated the correlation
within the expression profile of FcRY, B lymphocytes
population and HBV-induced diseases, especially
chronic infection, LC and HCC, with peripheral
blood. We believe that this report may provide valu-
able insights into HBV-induced disease pathology.
Material and methods
Samples. This study was conducted with the approval of
the local Ethics Committee of Wuxi Hospital of Infectious
Disease and Jiangsu Institute of Nuclear Medicine. All do-
nors gave written informed consent before blood was drawn.
Ninety-two subjects, including 27 healthy controls and 65
patients infected with HBV, were recruited from Wuxi Hos-
pital of Infectious Disease between 2008 and 2009 in the
present study. The patients were divided into four groups
according to the progression of HBV-induced diseases. The
first group comprised 27 healthy controls with no previous
evidence of any liver diseases and all serological HBV-viral
markers tested negative. The second group was 25 CHB
patients, who were hepatitis B surface antigen (HBsAg)-
-positive for more than six months and had histological ev-
idence of chronic hepatitis. The third group included 20
HBV-related LC patients, and the fourth group was 20 HBV-
-related HCC patients clinically and histologically diagnosed.
Clinicopathological data were retrospectively reviewed,
which included age, sex, serum bilirubin, albumin, AST and
ALT (Table 1).
Cell preparation. Heparinized peripheral blood samples
(10 ml) collected from the donors were diluted in PBS and
layered on Isopaque-Ficoll separation medium and centri-
fuged for 30 min at 400 × g. Peripheral blood mononuclear
cells (PBMC) accumulating at the interface were separated
and resuspended at RPMI 1640. CD19 B cells were isolat-
ed from PBMC using direct MACS kit (StemCell, Vancou-
ver, BC, Canada) according to the manufacturer’s instruc-
tion. The purity of cells was > 95% as determined by flow
cytometry.
Real-time PCR. Total RNA was extracted from sorted cells
using Trizol according to the manufacturer’s recommenda-
tions and first-strand cDNA synthesis using PrimeScriptTM
RT reagents Kit (Takara, Otsu, Shiga, Japan). Real-time
polymerase chain reaction (RT-PCR) was performed with
the cDNA using SYBR green PCR Master Mix (Takara,
Otsu, Shiga, Japan). Each amplification reaction underwent
denaturation at 95°C for 30 s, amplification for 40 cycles at
95°C for 5 s, annealing and extension at 60°C for 20 s using
LightCycler sequence detection system. Human FcRY gene-
-specific primers used for real-time PCR amplification were
5’GGG AGC ACC CGT CAG TGA 3’and 5’CTG GCG
CAT AGG GCA CTT 3’. The gene-specific primers of hu-
man housekeeping gene GAPDH were 5’AAC AGC CTC
AAG ATC ATC AGC 3’and 5’GGA TGA TGT TCT GGA
GAG CC 3’. Only those samples with a positive GAPDH
amplification were used for this study.
Flow cytometry. All blood samples were processed on the
day of collection and the antibodies used in this study were
purchased from BD Biosciences and R&D Systems. For the
detection of natural GC B cells, PBMC were stained with
peridinin chlorophyll protein (PerCP)-conjugated anti-
-CD19, fluorescein isothiocyanate (FITC)-conjugated anti-
Table 1. Clinical characteristics of the subjects enrolled in the study
Parameters HC (n = 27) CHB (n = 25) LC (n = 20) HCC (n = 20)
Age (years) 35.9 ± 7.2 37.2 ± 10.3 44.5 ± 10.1 40.2 ± 9.2
Sex (M/F) 10/6 14/11 7/3 6/4
Serum bilirubin [mg/mL] 0.6 ± 0.4 3.5 ± 10.7 22.4 ± 10.1 30.1 ± 18.6
Albumin [g/dL] 4.5 ± 1.9 4.2 ± 3.0 6.3 ± 3.9 5.5 ± 2.1
AST [IU/L] 19.3 ± 3.2 96.6 ± 45.3 116.0 ± 55.7 104.2 ± 62.7
ALT [IU/L] 15.4 ± 2.8 99.8 ± 28.2 98.8 ± 43.3 116.4 ± 50.3
HC — healthy controls; CHB — chronic hepatitis B; LC — liver cirrhosis; HCC — hepatocellular carcinoma; AST — aspartate aminotransferase;
ALT — alanine transaminase
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-CD38 and phycoerythrin (PE)-conjugated anti-IgD and gat-
ing was on CD19 B cells. For the detection of FcRY posi-
tively expressed B cells, PBMC was first fixed and perme-
abilized using 4% paraformaldehyde and ice-cold methanol
and then stained with PerCP-conjugated anti-CD19 and
FITC-conjugated anti-FcRY. After staining, cells were washed
twice and resuspended in fluorescence-activated cell sorting
solution, fixed in PBS containing 1% paraformaldehyde, and
analyzed in FACSCalibur system. Mouse isotype-matched
FITC, PE and PerCP were used as negative controls.
Statistical analysis. Demographic and clinical data were
presented as mean ± SD deviation. Differences between
variables were compared by the unpaired Student’s t-test,
and differences in proportions were compared by Fisher’s
exact test as appropriate. A p-value of < 0.05 was consid-
ered to be significant. Analysis of data was performed using
SPSS 13.0 (Chicago, IL, USA).
Results
Association of B cell frequency with
HBV-induced diseases
PBMC from healthy controls and HBV patients was
analyzed using flow cytometry for evidence of chron-
ic antigenic stimulation. First, the percentage of B cells
from PBMC in the four studied groups was investi-
gated by staining with anti-CD19 and anti-CD3. In
controls, the frequency of CD19 B cells ranged from
3.22% to 15% of gated lymphocytes. The range in
HBV patients was much greater, with CD19 B cell
frequencies ranging between 2.52% and 30.1% of
gated lymphocytes. The variance of the HBV patients’
B cell frequency data was significantly different from
that for the healthy controls (p < 0.05) but there was
no significant difference among patients of different
groups (Table 2).
To further investigate possible alteration of GC B
cells in different HBV-induced disease status, PBMC
were stained for anti-CD38 and anti-IgD of gated
CD19 B cells. A small proportion of GC B cells
(CD38+ IgD–) was found circulating in peripheral
blood and the percentage of GC B cells was signifi-
cantly increased in the patients compared to healthy
controls (p < 0.01). We next questioned whether the
percentage of GC B cells would vary within patients
of different disease status. We found that the propor-
tion of GC B cells of CHB patients was significantly
different compared to the other two groups (p < 0.05),
but there was no significant difference between LC
and HCC patients (Table 2).
Expression profile of FcRY in
different HBV-induced diseases
FcRY mRNA expression was detectable by quanti-
tative real-time PCR in 24 of 27 (89%) normal sam-
ples and 63 of 65 (97%) patient samples. Relative
expression of FcRY mRNA levels in B cells from
patients with HBV-induced diseases and healthy
controls was calculated by normalizing against
GAPDH. Significantly higher levels were found in
the HBV patients compared to healthy donors.
Furthermore, we found FcRY expression in CHB
patients was about 20-fold higher (p < 0.05). How-
ever, in patients with HBV-associated LC and HCC,
FcRY was about 500-fold higher (p < 0.01), com-
pared to healthy controls. In addition, there was
a significant difference for expression of FcRY gene
between CHB patients and the other two groups
(p < 0.05), but no significant difference between
LC and HCC patients (Figure 1).
Flow cytometric analysis of intracytoplasmic ex-
pression of FcRY protein was performed in B cells
from 87 clinical samples including 24 healthy con-
trols and 63 HBV-infected patients (Figure 2). As
expected, FcRY protein expression was observed in
87 samples. The FcRY levels on the CD19 B cells in
HCC (45.0% ± 15.1%) and LC (41.7% ± 13.3%)
patients were significantly higher compared to CHB
patients (11.4 ± 4.1%, p < 0.05) and healthy con-
trols (2.5 ± 1.2%, p < 0.01). Overall, the protein
expression pattern was similar to that obtained by
real-time PCR.
Table 2. Association of cell frequency with HBV-induced diseases
Trait CD19+CD3– CD19+CD38+IgD–
Mean ± SD (%) p Mean ± SD (%) p
HC (n = 27) 6.2 ± 2.5 – 0.8 ± 0.3 –
CHB (n =25) 8.4 ± 5.1 0.042 1.1 ± 0.5 0.031
LC (n = 20) 15.4 ± 9.3 0.017 3.7 ± 1.6 0.004
HCC (n = 20) 14.6 ± 8.5 0.023 4.2 ± 2.8 0.008
p values compared the patients group to the healthy controls group
408 K Wang et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2011
10.5603/FHC.2011.0057
www.fhc.viamedica.pl
These results indicated that the protein expres-
sion level of FcRY was indeed correlated positively
with their corresponding mRNA expression level
(Figure 3). The expression level of FcRY was signif-
icantly associated with the progression of HBV-re-
lated diseases.
Discussion
HBV infection is a serious problem worldwide, espe-
cially in China. A substantial number of HBV carri-
ers develop cirrhosis and HCC, but the mechanism
underlying the different outcomes among patients is
not clear [1–3]. In this study, we investigated the ex-
pression profile of FcRY and B lymphocytes popula-
tion in HBV-induced diseases to help clarify one as-
pect of the function of FcRY, which was over-ex-
pressed in HBV-induced diseases. Previous studies
failed to reveal any FcRY mRNA expression in pa-
tients with autoimmune diseases. However, expres-
sion of FcRY was found to be strongly enhanced in
malignant and metastatic melanomas compared to
that in melanocytic nevi [20]. To the best of our knowl-
edge, this study is the first to report the correlation of
FcRY expression profile, B lymphocytes population
from peripheral blood, and different stages of HBV
infection.
Since FcRY is preferentially expressed by B lym-
phocytes and largely limited to the germinal center B
cells, we measured the frequency of B lymphocytes
and germinal center B cell subpopulation of HBV-
-infected patients compared to healthy controls. The
percentage of the HBV patients’ B cells in PBMC was
significantly higher than that of the healthy controls.
Furthermore, the germinal center B cell subpopula-
tion was also increased in the course of HBV infec-
tion. The elevated presentation of this subpopulation
might be the result of B cell activation in this disease.
Then we measured the mRNA and protein expres-
sion level of FcRY in 92 samples including HBV-re-
lated patients and healthy donors.
The results showed FcRY expression increased as
the HBV-induced disease progressed from chronic
hepatitis to cirrhosis and HCC. In addition, up-regu-
lation of FcRY was indeed correlated positively with
their corresponding mRNA expression level. The rar-
ity of B cells expressing the FcRY gene in the blood
of healthy donors may be explained by the low per-
centage of GC B cells in the peripheral blood of
healthy donors and an increased expression level of
FcRY may correlate with change of GC B cells in
Figure 1. mRNA expression of FcRY on B lymphocytes
from peripheral blood in patients with HBV-induced
diseases and healthy controls; *p < 0.05; **p < 0.01
Figure 2. Protein expression of FcRY on B lymphocytes
from peripheral blood in patients with HBV-induced
diseases and healthy controls. A: healthy control;
B: CHB patient; C: LC patient; D: HCC patient
Figure 3. Comparision of mRNA and protein expression
level of FcRY in 87 subjects. The real-time PCR results
represent the relative values of FcRY mRNA expression to
that of GAPDH multiplied by 100,000. The flow cytometry
results are presented as percentage
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peripheral blood under the pathological progression.
However, the mechanism by which HBV antigen af-
fects the function of B lymphocytes is unclear and
needs to be addressed in future studies.
In conclusion, the results of our study suggest that
B lymphocytes are more active in HBV-induced dis-
eases because of the increased proportion of GC
B cells. And the detection of increased FcRY mainly
expressed on GC B cells is associated with a high risk
of HBV chronic infection development into cirrhosis
and HCC. So FcRY is perhaps one of the B cell acti-
vation markers.
However, it is not yet clear if activation of B lym-
phocytes and up-expression of FcRY are the cause,
or the outcome, of the disease progression. Additional
studies are underway to elucidate the molecular mech-
anism and the more detailed function of FcRY and
B lymphocytes in HBV-induced diseases.
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